Loading…
Loading…
As of 20 Nov 2026: Earkart ₹102.00 (m-cap ₹141 Cr, P/E 28.5) vs GKB Ophthalmics ₹57.00 (m-cap ₹28.50 Cr, P/E 12.5). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Earkart | GKB Ophthalmics |
|---|---|---|
| Share price | ₹102.00 | ₹57.00 |
| Day change | 0.00% | −2.80% |
| Market cap | ₹141 Cr | ₹28.50 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 28.5 | 12.5 |
| P/BPrice ÷ book value per share. | 2.2 | 0.5 |
| ROEReturn on equity. | — | 3.3% |
| ROCEReturn on capital employed. | — | 11.0% |
| Sales growth (3Y CAGR) | 23.2% | 25.5% |
| Profit growth (3Y CAGR) | 55.6% | 138.0% |
| Debt to equity | 0.00 | 0.22 |
| Dividend yield | 0.00% | 0.00% |
| 1-year price return | −50.2% | −3.5% |
| Promoter holding | 57.3% | 51.2% |
| Industry | Medical Equipment & Supplies | Medical Equipment & Supplies |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Earkart Limited is larger, with a market cap of ₹141 Cr against ₹28.50 Cr for GKB Ophthalmics Ltd as of 20 Nov 2026 — about 4.9 times the size.
GKB Ophthalmics Ltd trades at a P/E of 12.5 against 28.5 for Earkart Limited as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.